Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer) in Subjects With Inflammatory Bowel Disease

Trial Profile

An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer) in Subjects With Inflammatory Bowel Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric derisomaltose (Primary)
  • Indications Inflammatory bowel diseases; Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 03 Dec 2013 New trial record
    • 01 Nov 2011 Recruitment completed, according to results published in the Scandinavian Journal of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top